Alphatec Holdings, Inc. ATEC R2K
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 29.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 65.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATEC Alphatec Holdings, Inc. R2K | 7.75 | - | $1.19B | - | -17.04% | - | 29.62% | 1.75% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.17M | 51.01M | 53.63M | 35.58M | 32.33M | 31.69M | 34.79M | 34.21M | 32.24M | 26.71M | 27.09M | 27.98M | 24.38M | 23.10M | 21.31M | 22.04M | 23.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 169.18M | 185.54M | 196.50M | 212.93M | 192.11M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.18M | 56.44M | 59.20M | 63.44M | 55.63M |
| Gross Profit | 36.12M | 36.31M | 37.69M | 24.49M | 18.29M | 21.66M | 23.59M | 24.49M | 21.16M | 15.86M | 14.63M | 16.78M | 15.75M | 14.51M | 14.90M | 15.55M | 16.21M | 16.57M | 18.89M | 19.93M | 21.03M | 20.84M | 29.24M | 31.86M | 41.06M | 39.61M | 49.22M | 55.48M | 59.52M | 70.42M | 64.54M | 80.05M | 97.35M | 102.59M | 102.73M | 116.00M | 129.10M | 137.30M | 149.49M | 136.48M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.70M | 140.59M | 146.71M | 154.85M | 158.53M |
| Operating Income | 1.84M | 1.73M | - | 1.14M | -2.83M | -164.68M | - | -3.44M | -320.00K | -4.55M | - | -3.40M | -735.00K | -1.26M | -667.00K | -6.54M | -7.53M | -10.77M | -10.41M | -11.60M | -17.81M | -11.16M | -12.86M | -19.05M | -35.75M | -35.12M | -41.23M | -35.75M | -34.97M | -40.35M | -49.86M | -38.36M | -43.34M | -35.31M | -33.70M | -31.71M | -11.48M | -9.41M | -5.36M | -22.06M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.95M | -8.35M | 4.75M | 11.63M | -1.68M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.84M | 12.31M | 12.88M | 12.89M | 11.72M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -51.97M | -41.18M | -28.50M | -21.75M | -33.86M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -64.00K | -37.00K | 74.00K | -18.00K | 50.00K |
| Net Income | -2.90M | -3.04M | -273.00K | -4.56M | -3.95M | -160.26M | -9.90M | -6.62M | -5.23M | -13.72M | -4.35M | -5.51M | -2.70M | -3.14M | -1.92M | -7.08M | -9.36M | -12.97M | -12.44M | -14.57M | -20.72M | -15.80M | -15.67M | -22.90M | -38.20M | -43.03M | -42.62M | -37.10M | -36.79M | -43.53M | -51.38M | -42.65M | -48.49M | -40.68M | -39.62M | -51.91M | -41.14M | -28.58M | -21.73M | -33.91M |
| Diluted EPS | -0.03 | -0.04 | -0.03 | -0.05 | -0.04 | -1.61 | -0.10 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.39 | -0.43 | -0.43 | -0.36 | -0.35 | -0.40 | -0.43 | -0.35 | -0.34 | -0.29 | -0.28 | -0.35 | -0.27 | -0.19 | -0.14 | -0.22 |
| R&D Expense | 4.53M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.62M | 171.61M | 197.71M | 196.28M | 204.72M | 154.62M | 134.39M | 120.25M | 101.74M | - | - | - | - | 350.87M | 482.26M | 611.56M | 764.15M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 117.81M | 172.06M | 187.30M | 232.27M |
| Gross Profit | 81.01M | 112.82M | 116.93M | 123.77M | 124.32M | 109.67M | 88.02M | 76.13M | 68.22M | 63.24M | 77.59M | 102.50M | 157.76M | 233.06M | 310.20M | 424.26M | 531.89M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 354.16M | 458.48M | 547.17M | 589.85M |
| Operating Income | -10.19M | -11.79M | -24.52M | -9.84M | -73.43M | 1.49M | -175.85M | -15.38M | -9.00M | -22.44M | -47.28M | -58.86M | -128.06M | -121.10M | -148.28M | -122.91M | -57.97M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -102.58M | -110.59M | -53.87M | -14.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.50M | 16.64M | 24.88M | 45.92M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -152.01M | -186.91M | -162.07M | -143.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -716.00K | -277.00K | 50.00K | -45.00K |
| Net Income | -13.29M | -14.36M | -22.18M | -15.46M | -82.23M | -12.88M | -178.68M | -29.93M | -2.29M | -28.98M | -57.00M | -78.99M | -143.03M | -151.29M | -186.64M | -162.12M | -143.36M |
| Diluted EPS | - | - | - | -0.17 | -0.85 | -1.90 | -21.53 | -3.49 | -1.08 | -1.20 | - | -1.18 | -1.49 | -1.47 | -1.54 | -1.13 | -0.96 |
| R&D Expense | 13.49M | 16.43M | 16.89M | 14.89M | 14.19M | 16.80M | 17.77M | - | - | - | - | - | - | - | - | - | - |
Compounded Sales Growth
| 5 Years: | 29.62% |
| 1 Year: | 13.60% |
Compounded Profit Growth
| 5 Years: | 1.75% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -37.65% |
| 6 Months: | -64.50% |
| 3 Months: | -43.10% |
| 1 Month: | -16.67% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 377.02M | 366.69M | 382.13M | 365.63M | 344.92M | 146.34M | 94.19M | 84.66M | 129.48M | 169.95M | 261.22M | - | 520.97M | 805.21M | 775.71M | 791.21M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 255.63M | 451.09M | 417.40M | 450.88M |
| Cash & Equivalents | 18.32M | 10.09M | 23.17M | 20.67M | 22.24M | 21.34M | 19.73M | 11.23M | 19.59M | 22.47M | 29.05M | - | 107.77M | - | 84.70M | 220.97M | 138.84M | 160.81M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 101.52M | 136.84M | 175.26M | 169.44M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.06M | 72.61M | 82.99M | 97.30M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 555.63M | 727.09M | 789.88M | 778.78M |
| Current Liabilities | - | - | 43.59M | 57.14M | 56.79M | 79.72M | 63.60M | 125.04M | 40.13M | 29.74M | 30.61M | 36.39M | 58.31M | - | 138.87M | 157.57M | 153.03M | 219.18M |
| Long Term Debt | - | - | 32.47M | 23.80M | 39.97M | 49.98M | 74.60M | 480.00K | 43.09M | 37.77M | 42.30M | 53.45M | 38.00M | - | 349.51M | 511.04M | 574.52M | 501.41M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 395.86M | 541.68M | 609.94M | 596.09M |
| Total Equity | - | - | - | - | - | 171.68M | 148.95M | -36.58M | -41.50M | -26.66M | 17.57M | 43.63M | 129.88M | - | -34.67M | 78.12M | -14.17M | 12.43M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 108.45M | 141.05M | 145.94M | 150.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.55M | -14.83M | 13.41M | 11.59M | 7.81M | -20.27M | 10.12M | -9.96M | -8.73M | -25.61M | -33.12M | -46.41M | - | -75.13M | -78.48M | -44.65M | 45.23M |
| Investing Cash Flow | -12.73M | -14.41M | -9.52M | -19.40M | -19.10M | -11.00M | -12.25M | 61.96M | -6.50M | -21.67M | -13.03M | -23.86M | - | -58.28M | -141.97M | -93.14M | -53.41M |
| Financing Cash Flow | 10.27M | 43.06M | -6.92M | 8.48M | 10.69M | 30.73M | -6.53M | -43.39M | 17.82M | 53.88M | 64.18M | 130.83M | - | 31.23M | 356.92M | 56.21M | 30.02M |
| Capital Expenditure | -11.76M | -14.03M | -8.21M | -15.65M | -14.35M | -11.30M | -12.25M | -8.90M | -7.60M | -6.51M | -13.03M | -23.13M | - | -58.28M | -86.97M | -93.14M | -49.64M |
| Free Cash Flow | -17.31M | -28.86M | 5.20M | -4.05M | -6.54M | -31.57M | -2.12M | -18.86M | -16.32M | -32.12M | -46.15M | -69.54M | - | -133.41M | -165.46M | -137.79M | -4.41M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -102.19M | 136.46M | -81.58M | 21.84M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 25.00M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 67.2% | 65.7% | 59.1% | 63.1% | 60.7% | 70.9% | 65.5% | 63.3% | 67.1% | - | - | - | - | 66.4% | 64.3% | 69.4% | 69.6% |
| Operating Margin % | -8.4% | -6.9% | -12.4% | -5.0% | -35.9% | 1.0% | -130.9% | -12.8% | -8.8% | - | - | - | - | -34.5% | -30.7% | -20.1% | -7.6% |
| Net Margin % | -11.0% | -8.4% | -11.2% | -7.9% | -40.2% | -8.3% | -133.0% | -24.9% | -2.3% | - | - | - | - | -43.1% | -38.7% | -26.5% | -18.8% |
| ROE % | - | - | - | - | -47.9% | -8.6% | 488.5% | 72.1% | 8.6% | -164.9% | -130.6% | -60.8% | - | 436.4% | -238.9% | 1,144.2% | -1,153.8% |
| ROCE % | - | -3.5% | -7.9% | -3.0% | -25.7% | 0.5% | -825.5% | -28.4% | -16.4% | -22.7% | -35.4% | -29.0% | - | -31.7% | -22.9% | -19.7% | -10.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.56% | 10.09M | $78.18M |
| 2 | American Century Companies Inc | 4.18% | 6.42M | $49.79M |
| 3 | Vanguard Capital Management LLC | 3.20% | 4.91M | $38.08M |
| 4 | Royal Bank of Canada | 2.94% | 4.52M | $35.00M |
| 5 | BNP Paribas Asset Management Holding S.A. | 2.35% | 3.62M | $28.03M |
| 6 | State Street Corporation | 1.97% | 3.03M | $23.49M |
| 7 | Geode Capital Management, LLC | 1.89% | 2.91M | $22.52M |
| 8 | Nuveen, LLC | 1.85% | 2.85M | $22.08M |
| 9 | Millennium Management Llc | 1.83% | 2.81M | $21.77M |
| 10 | Bank of America Corporation | 1.67% | 2.56M | $19.85M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATEC